Question 1

Is tirzepatide FDA-approved for MASH?

Accepted Answer

No. As of May 2026, tirzepatide is FDA-approved for type 2 diabetes (Mounjaro), chronic weight management (Zepbound), and obstructive sleep apnea in adults with obesity. SYNERGY-NASH is a phase 2 trial — the data are proof-of-concept, not registration-grade. Eli Lilly has announced a phase 3 MASH program, but those trials have not yet read out. The only FDA-approved MASH drug is resmetirom (Rezdiffra), which received accelerated approval in March 2024 based on histologic surrogate endpoints. Treating MASH with tirzepatide is off-label in the United States; insurance coverage for that indication is not standard.

Question 2

How does SYNERGY-NASH compare to ESSENCE (semaglutide for MASH)?

Accepted Answer

Both trials test GLP-1-class drugs in biopsy-proven MASH with significant fibrosis, but they differ in dose, drug class, and reported magnitude. SYNERGY-NASH is phase 2, n=190, 52 weeks, tirzepatide 5/10/15 mg, with 62% MASH resolution at 15 mg vs 10% placebo. ESSENCE (Sanyal 2025, NEJM) is phase 3, n=1,200+, 72-week interim analysis, semaglutide 2.4 mg, with about 63% MASH resolution vs 34% placebo and about 37% fibrosis improvement vs 22% placebo. Cross-trial comparisons should be made cautiously because populations and biopsy adjudication panels differ. Tirzepatide's tighter dose-response on histology suggests dual incretin agonism may add to GLP-1-only mechanisms, but a head-to-head trial would be needed to establish superiority.

Question 3

Why does the trial require a liver biopsy?

Accepted Answer

MASH is defined histologically — by the presence of steatosis plus inflammation plus hepatocyte ballooning on liver tissue, with a separate fibrosis stage from F0 to F4. Non-invasive tests (FibroScan, MRI-PDFF, ALT, FIB-4) correlate with biopsy findings but cannot reliably substitute for it when the question is whether a drug resolves the underlying disease. The FDA's accelerated-approval pathway for MASH requires paired biopsies at baseline and at the endpoint timepoint, with central adjudication of MASH resolution and fibrosis change by blinded pathologists. SYNERGY-NASH followed this design exactly: every participant underwent a baseline biopsy to confirm eligibility and a week-52 biopsy to adjudicate the primary endpoint. This is why MASH trials are small and slow compared with obesity trials of the same drug.

Question 4

Is the fibrosis improvement durable?

Accepted Answer

SYNERGY-NASH only ran 52 weeks with one paired biopsy, so the trial cannot answer the durability question directly. The biology of fibrosis suggests improvements are likely to persist while the underlying driver (metabolic dysfunction) is controlled, but reverse — fibrosis re-accumulation — if treatment stops. The pattern matches what STEP-4 showed for semaglutide on body weight: maintenance on drug, partial reversal off drug. Phase 3 MASH trials and post-marketing studies, when they read out, will need to address fibrosis durability over multiple years. Until then, clinicians and patients should treat MASH as a chronic disease that requires chronic therapy, not a finite course.

Question 5

Should obese patients with normal liver enzymes still worry about MASH?

Accepted Answer

Yes, often. Normal ALT and AST do not rule out MASH or significant fibrosis. Population studies estimate that 20-30% of adults with obesity have steatotic liver disease, and a meaningful fraction have steatohepatitis or fibrosis even with enzyme values inside reference ranges. Non-invasive screening with FIB-4 (calculated from age, AST, ALT, and platelets) and FibroScan or MRI-PDFF can identify higher-risk patients who should be referred to hepatology. The American Association for the Study of Liver Diseases (AASLD) 2023 guidance recommends screening adults with type 2 diabetes, obesity with cardiometabolic risk factors, or a family history of cirrhosis for steatotic liver disease, regardless of enzyme status. If you have obesity and are starting a GLP-1, ask whether a FIB-4 calculation belongs on your baseline lab order.

Question 6

Does the weight loss explain the MASH improvement?

Accepted Answer

Partially, but probably not fully. Weight loss of 10% or more is itself associated with MASH resolution rates of roughly 40-50% in lifestyle-intervention studies, so a portion of the tirzepatide effect in SYNERGY-NASH is mediated through weight loss. However, the placebo arm lost only 2.3% and resolved MASH in 10%, while the 15 mg arm lost 15.6% and resolved MASH in 62% — a steeper relationship than would be expected from weight loss alone. The tirzepatide arms also showed improvements in liver fat by MRI-PDFF that exceeded what would be predicted from weight change. The implication is that direct hepatic and adipose effects of GLP-1/GIP agonism contribute on top of the weight-loss-mediated pathway, though the full mechanistic decomposition has not been published.

Endpoint	Treatment	Comparator	Difference
Improvement of ≥1 fibrosis stage without worsening of MASH at week 52 (key secondary, paired biopsy) Fibrosis improvement is the second pillar of the FDA's MASH regulatory framework. The flat dose-response across 5/10/15 mg suggests the fibrosis effect may saturate at lower doses than the steatohepatitis-resolution effect.	15 mg: 51% (95% CI 35-66); 10 mg: 51% (95% CI 35-67); 5 mg: 55% (95% CI 39-71)	Placebo: 30% (95% CI 15-44)	Numerically higher on all tirzepatide doses; statistical significance not consistently reached across all dose comparisons in the primary analysis
Percent change in body weight at week 52 Weight-loss magnitudes consistent with what tirzepatide produces in obesity trials at the same doses (SURMOUNT-1), but with a slightly attenuated effect at 52 weeks vs 72 weeks.	15 mg: -15.6%; 10 mg: -13.3%; 5 mg: -10.7%	-2.3%	Placebo-subtracted: -13.3 (15 mg), -11.0 (10 mg), -8.4 (5 mg) percentage points
Absolute change in NAFLD activity score (NAS) at week 52 NAS sums steatosis (0-3), lobular inflammation (0-3), and hepatocyte ballooning (0-2) on a 0-8 scale. A drop of ≥2 with at least 1 point from ballooning or inflammation is the histologic substrate for MASH resolution.	15 mg: -3.0; 10 mg: -3.0; 5 mg: -2.6	-1.0	Placebo-subtracted reductions of 1.6-2.0 points; all three doses significantly different from placebo
Relative change in liver fat (MRI-PDFF) at week 52 Magnetic resonance proton-density fat fraction is a non-invasive surrogate for hepatic steatosis. A 30% relative reduction predicts histologic response.	15 mg: -59%; 10 mg: -52%; 5 mg: -43%	-10%	All three doses significantly different from placebo
Change in alanine aminotransferase (ALT) at week 52 ALT normalization correlates with MASH improvement but is not used in isolation for regulatory endpoints.	15 mg: -28 U/L; 10 mg: -24 U/L; 5 mg: -28 U/L	-10 U/L	Placebo-subtracted reductions of 14-18 U/L across tirzepatide doses
Change in aspartate aminotransferase (AST) at week 52	15 mg: -16 U/L; 10 mg: -14 U/L; 5 mg: -17 U/L	-7 U/L	Placebo-subtracted reductions of 7-10 U/L across tirzepatide doses
Change in HbA1c at week 52 (participants with T2DM at baseline) Consistent with the SURPASS phase 3 program in T2DM. The non-T2DM subgroup also showed small HbA1c reductions of about 0.4 percentage points.	15 mg: -1.6%; 10 mg: -1.6%; 5 mg: -1.3%	-0.3%	Placebo-subtracted reductions of 1.0-1.3 percentage points in the T2DM subgroup
Change in liver stiffness by vibration-controlled transient elastography (FibroScan, kPa) at week 52 FibroScan is a non-invasive correlate of fibrosis; the directional improvement supports the biopsy-based fibrosis-improvement finding.	15 mg: -3.7 kPa; 10 mg: -3.1 kPa; 5 mg: -2.5 kPa	-0.5 kPa	All three tirzepatide doses produced larger reductions in liver stiffness than placebo

Event	Treatment rate	Comparator rate
Nausea (most-common AE) Most cases mild-to-moderate; clustered during dose-escalation. Dose-dependent pattern consistent with obesity and T2DM trials.	5 mg: 18%; 10 mg: 34%; 15 mg: 32%	13%
Diarrhea Numerically higher on tirzepatide; not strongly dose-dependent.	5 mg: 23%; 10 mg: 13%; 15 mg: 23%	13%
Constipation	5 mg: 8%; 10 mg: 17%; 15 mg: 19%	13%
Vomiting Dose-dependent; consistent with GLP-1/GIP class profile.	5 mg: 5%; 10 mg: 9%; 15 mg: 13%	0%
Decreased appetite Part of mechanism rather than a complication per se.	5 mg: 18%; 10 mg: 11%; 15 mg: 21%	0%
COVID-19 (study ran 2020-2023, reported as AE) Reflects pandemic-era enrollment; not a treatment-related signal.	5 mg: 25%; 10 mg: 23%; 15 mg: 21%	13%
Discontinuation due to adverse event Lower than reported in obesity or T2DM trials, possibly reflecting the smaller phase 2 sample size.	5 mg: 3%; 10 mg: 6%; 15 mg: 4%	0%
Serious adverse events (any) No imbalance between tirzepatide and placebo arms; no signal for hepatic decompensation.	5 mg: 8%; 10 mg: 6%; 15 mg: 8%	10%
Adjudicated acute pancreatitis No cases reported in any arm during the 52-week treatment period.	0% across all tirzepatide arms	0%

SYNERGY-NASH deep-dive: tirzepatide for MASH with fibrosis (Loomba 2024 NEJM)

Primary endpoint

Secondary endpoints

Adverse events

Subgroup analyses

Clinical significance

Frequently Asked Questions

References

Related trial deep-dives